GlassScriptPhysician profile
Christian E Ellison
NPI 1306838305
$2,302.70
in general payments reported to CMS, 2019-2025
27 companies · $34.79 in 2025
The $34.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $362 · 2023: $16.44 · 2024: $30.08 · 2025: $34.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $289.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $284.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $235.49 | 2019-2020 | |
| Novo Nordisk INC | $211.28 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.95 | 2019-2020 | |
| Viiv Healthcare Company | $138.29 | 2019-2025 | Dovato |
| Amarin Pharma, INC. | $119.07 | 2019-2020 | |
| Lilly USA, LLC | $111.81 | 2019-2020 | |
| Gilead Sciences, INC. | $98.46 | 2019-2020 | |
| Amgen INC. | $74.61 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $71.65 | 2019 | |
| Janssen Biotech, INC. | $55.91 | 2019 | |
| Pfizer INC. | $51.98 | 2019-2020 | |
| Theratechnologies INC. | $44.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.12 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $42.21 | 2019 | |
| Abbott Laboratories | $41.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.15 | 2019 | |
| Daiichi Sankyo INC. | $37.97 | 2019-2020 | |
| Becton, Dickinson and Company | $33.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2019 | |
| Ibsa Pharma INC. | $23.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2019 | |
| Shire North American Group INC | $14.92 | 2019 | |
| Vivus LLC | $14.21 | 2019 | |
| Abbvie INC. | $12.86 | 2019 | |
| Lifescan, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.